AesculaTech

AesculaTech is dedicated to enhancing lives through the application of intelligent chemistry. The company specializes in the creation of customized smart materials designed for diverse biomedical, commercial, and industrial purposes. At the heart of their innovation is AesculaGel, a platform technology that offers adaptive responses to a broad spectrum of stimuli. This material can be precisely engineered to meet specific requirements for biocompatibility, material strength, and other critical characteristics.

Founded by an MIT 35 under 35 Innovator, AesculaTech represents the collaborative vision of scientists, engineers, and medical professionals. Their primary product, Humidifeye, is an ophthalmic solution developed to address dry eye disease. This condition affects over 25 million individuals in the United States alone, and the global market for its treatment is anticipated to exceed $6 billion within the next ten years. AesculaTech's thermally responsive, form-fitting materials offer sustained yet reversible occlusion, accommodating various treatment durations. Unlike existing solutions, Humidifeye is designed to avoid extrusion and minimize patient discomfort through its adaptive properties. While awaiting FDA approval, Humidifeye holds significant promise for the future of dry eye treatment.

Working with partners across multiple industries, AesculaTech is actively developing a range of innovative technologies aligned with their core mission. Their efforts have garnered recognition, including being named a Rosenman Innovator, receiving a National Science Foundation I-Corps grant, becoming a finalist in the 2019 Octane High Tech Awards, and graduating from both the Y Combinator and TMCx accelerator programs. Y Combinator served as a foundational step in their journey.